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Abstract
Background: Plasmodium falciparum malaria is a significant public health problem in Comoros, and artemisinin
combination therapy (ACT) remains the first choice for treating acute uncomplicated P. falciparum. The emergence
and spread of artemisinin-resistant P. falciparum in Southeast Asia, associated with mutations in K13-propeller gene,
poses a potential threat to ACT efficacy. Detection of mutations in the P. falciparum K13-propeller gene may provide
the first-hand information on changes in parasite susceptibility to artemisinin. The objective of this study is to
determinate the prevalence of mutant K13-propeller gene among the P. falciparum isolates collected from Grande
Comore Island, Union of Comoros, where ACT has been in use since 2004.
Methods: A total of 207 P. falciparum clinical isolates were collected from the island during March 2006 and October
2007 (n = 118) and March 2013 and December 2014 (n = 89). All isolates were analysed for single nucleotide
polymorphisms (SNPs) and haplotypes in the K13-propeller gene using nested PCR and DNA sequencing.
Results: Only three 2006–2007 samples carried SNPs in the K13-propeller gene, one having a synonymous (G538G) and
the other having two non-synonymous (S477Y and D584E) substitutions leading to two mutated haplotypes (2.2 %, 2/95).
Three synonymous mutations (R471R, Y500Y, and G538G) (5.9 %, 5/85) and 7 non-synonymous substitutions (21.2 %, 18/
85) with nine mutated haplotypes (18.8 %, 16/85) were found in isolates from 2013 to 2014. However, none of the
polymorphisms associated with artemisinin-resistance in Southeast Asia was detected from any of the parasites examined.
Conclusion: This study showed increased K13-propeller gene diversity among P. falciparum populations on the Island
over the course of 8 years (2006–2014). Nevertheless, none of the polymorphisms known to be associated
with artemisinin resistance in Asia was detected in the parasite populations examined. Our data suggest that P. falciparum
populations in Grande Comore are still effectively susceptible to artemisinin. Our results provide insights into P. falciparum
populations regarding mutations in the gene associated with artemisinin resistance and will be useful for developing and
updating anti-malarial guidance in Comoros.
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Background
Malaria remains one of the major public health problems
throughout the world, with the occurrence of estimated
225 million clinical cases and ~600,000 deaths annually
[1]. In the Union of Comoros, Plasmodium falciparum
malaria is the most widespread species of human malaria
parasites, and was responsible for 15 % ~ 20 % of the regis-
tered deaths historically [2]. Over the past six decades,
chloroquine (CQ) had been used to cure and/or to pre-
vent malaria in Comoros [3]. Nevertheless, the increasing
emergence and spread of CQ-resistant P. falciparum led
to the use of the combination sulfadoxine-pyrimethamine
(SP) as first-line treatment for acute uncomplicated P. fal-
ciparum malaria in Comoros [3, 4]. Unfortunately, malaria
control in Comoros had been imperiled by the emergence
and spread of CQ- and SP-resistant P. falciparum in the
early 1980s and of DDT-resistant Anopheles mosquitoes
[5, 6]. In 2004, more than 100,000 malaria cases were
reported in Comoros, with high level incidence (~35 %)
[1]. Based on these observations, the government of
Comoros introduced artemisinin combination therapy
(ACT, artemether-lumefantrine) as first-line therapy for
uncomplicated P. falciparum malaria, and officially with-
drew the use of CQ and SP in 2004 [4, 5]. Unfortunately,
the ACT regime did not lead to decrease of malaria inci-
dence, with approximately 100,000 annual malaria cases
recorded from 2006 to 2012. Thus, malaria still represents
one of the major public health challenges in Comoros,
being responsible for ~38 % out-patient consultations and
~60 % of all hospitalizations. A countrywide malaria
control and elimination policy was launched by the gov-
ernment of Comoros in 2006, with the goal to basically
control malaria by 2015 and to completely eliminate
malaria by 2020. To block malaria transmission in this en-
demic area, mass drug administration with therapeutical
dose of artemisinin-piperaquine and low-dose of prima-
quine (Artepharm Co. Ltd, PR China) was launched by
late 2013 on Grande Comore Island. The effort has accel-
erated with impetus from the Global Fund in 2012, in
which large-scale distribution of insecticide-treated
mosquito nets has also been gradually implemented on
Grande Comore, Moheli, and Anjouan Islands, Union of
Comoros [4], hoping to reach up to 89.1 and 46.3 % of the
households with at least 1 mosquito net and 1 insecticide-
impregnated mosquito net, respectively. Consequently,
the annual malaria cases dramatically changed from
114,537 in 2007 to 2142 in 2014 (a 98.0 % reduction). To
achieve the goal of malaria elimination, there is an urgent
need to monitor parasite susceptibility to artemisinin, and
to develop and update anti-malarial guidance in Comoros.
ACT has been implemented world-wide as the first-line
treatment for acute uncomplicated P. falciparum malaria
since 2001, and has been responsible for the reduction
in malaria-associated mortality and morbidity [7, 8].
Currently, artemisinin-resistant P. falciparum parasites
have been reported mostly in Southeast Asia, including
Cambodia, Thailand, Myanmar, Vietnam, and Laos
[9–15]. Previous experience with the spread of CQ-
and SP-resistant parasites from Asia to Africa suggests
that the spread of artemisinin resistance to other parts of
the world is likely, and that vigilant surveillance for arte-
misinin resistant parasites is important for controlling the
spread of resistance [16–18]. Therapeutic efficacy studies
under field conditions, considered the gold standard for
determining anti-malarial drug efficacy, is currently com-
plicated primarily due to limited numbers of malaria indi-
viduals available in low malaria transmission areas [19].
Therefore, molecular genetic markers of resistance are
also useful for monitoring the emergence and spread of
anti-malarial drug resistance [20, 21]. Mutations and vari-
ations in expression of several genes such as pfmdr1 and
pfatpase6 have been suggested, but not proven, to be the
molecular marker of artemisinin resistance [22–24].
Recent studies have shown that artemisinin resistance is
associated with non-synonymous single-nucleotide poly-
morphisms (SNPs) in a P. falciparum gene with kelch
propeller domain (K13-propeller, PF3D7_1343700) in
Southeast Asia [12, 13, 25, 26]. Specifically, three muta-
tions (C580Y, R539T and Y493H) in the K13-propeller
gene were strongly associated with increased ring stage
survival and delayed parasite clearance [12]. Meanwhile,
artemisinin tolerance in vitro was associated with the
M476I mutation of K13-propeller [12].
As resistance to earlier anti-malarial drugs (CQ and SP)
spread from Asia to Africa and other parts of world
through parasite migration, there is a serious concern that
a similar scenario may occur with artemisinin resistance
[16–18]. Recently, it was reported that highly artemisinin-
resistant parasites could also emerge independently in
Southeast Asia, indicating that K13-propeller gene
polymorphisms have multiple origins throughout Africa
as well as Southeast Asia [26]. Comoros is a malaria-
endemic country with a history of ACT (artemether-lume-
fantrine) use since 2004, and a mass drug administration
(MDA) of artemisinin-piperaquine plus low-dose of
primaquine was launched for blocking malaria transmis-
sion on Grande Comore Island in 2013. Under such con-
tinuous and widespread artemisinin selective pressure, it
can be expected that a similar phenomenon seen in
Southeast Asia may occur in Comoros. Currently, no mo-
lecular epidemiologic information on P. falciparum para-
site populations on Grande Comore Island in response to
artemisinin is avaialable. Therefore, the aim of this study
is to investigate the frequencies and patterns of mutations
in K13-propeller gene linked to artemisinin resistance of
Grande Comore P. falciparum clinical isolates. Our data
will provide important information for molecular surveil-
lance of artemisinin-resistant P. falciparum in this area.
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Methods
Ethical statement
The study protocol was reviewed and approved by the
Ethics Committees of Comoros Ministry of Health (proto-
col No. 12521/MSSPG/CAB) and Guangzhou University
of Chinese Medicine (protocol No. 2012L0816). A written
informed consent form was read and signed by all partici-
pants before any study procedure was performed. The in-
dividuals who could not read and write in the language,
signed the form with their thumb print after it was
completed by an independent witness on their behalf.
Study sites
The study was conducted on Grande Comore Island,
Union of Comoros (latitude 11°00′-12°00′S; longitude 43°
10′-43°35′E), in the Indian Ocean between Madagascar
and the eastern coast of Africa (Fig. 1). This island has an
area of 1147 km2 with a human population around
420,000 in 2012. The climate of this island is characterized
by a warm, wet summer, and a cool, dry winter. The area
has a distinct seasonal climate characterized by rainy sea-
son (November-April) and dry season (May-October),
with temperature ranging from 11 to 35 °C and rainfall
ranging from 1000 to 3000 mm annually. This island was
a highly endemic area for P. falciparum and P. malariae
malaria, with P. falciparum being the most common spe-
cies (>95.5 %) [27]. Malaria transmission is perennial, with
a peak during the rainy season throughout this island.
Four confirmed Anopheles species (Anopheles gambiae,
An. funestus, An. merus, and An. coustani) are present on
this island, with An. gambiae being the predominant
vector [27].
Study samples
Blood samples were collected from patients with symp-
tomatic P. falciparum malaria admitted to Mitsoudje Cen-
ter Hospital, National Malaria Center, and Mitsamiouli
Center Hospital for anti-malarial drug treatment (Fig. 1).
After informed consent from all adults or legal guardians
of children, thick and thin blood smears were prepared
and were stained with 10 % Giemsa to diagnose human
malaria species. Patients infected with P. falciparum only
(no other human malaria species) as confirmed by periph-
eral smear examination were included in this study. One
study was conducted between March 2006 and October
2007, and the other between March 2013 and December
2014. From each individual, a 1.0 ml of whole blood sam-
ple was collected in an EDTA tube and stored at −20 °C
until DNA extraction. A total of 207 P. falciparum clinical
isolates were collected on Grande Comore Island in one
period March 2006 and October 2007 (n = 118), and in
another period March 2013 and December 2014 (n = 89).
Extraction of parasite DNA
Genomic DNA was extracted from 100 μL of each whole
blood sample using DNA blood kit according to the
manufacturer’s protocol (Takara, Japan). The extracted
DNA was eluted in 60 μL of TE buffer (10 mM Tris–
HCl, 0.1 M EDTA, pH 8.0) and stored at −20 °C until
use. The quality of genomic DNA was detected using
1.0 % agarose gel electrophoresis and goldviewer buffer
staining used as ethidium bromide substitute (Sangon
Bio Inc., Shanghai, China).
PCR amplification and sequencing of P. falciparum
K13-propeller
To amplify the P. falciparum K13-propeller, a nested
PCR amplification method was used following previously
reported protocols [12]. Oligonucleotide primers and
cycling conditions are listed in Table 1. The total 25 μl
amplification reaction mixtures contained 8.5 ~ 10.0 μl
of dH2O, 1.0 μl of each primer (10 pM), and 12.5 μl of
Taq PCR Master Mix following the manufacturer’s in-
structions (Sangon Bio Inc., Shanghai, China). Primary
amplification reactions were initiated with the addition
of 2.0 μL of template genomic DNA prepared from the
blood samples. For the nested PCR, 0.5 μL of primary
PCR productions was used as template. The amplified
PCR products were detected on 2 % agarose gel, and the
sizes of the PCR products were measured visually based
on a 100 bp DNA ladder (Sangon Bio Inc., Shanghai,
China). The nested PCR products of K13-propeller were
Fig. 1 Map of Grande Comore Island, Union of Comoros. Shown are the locations of Mitsoudje Center Hospital (□), National Malaria Center (○),
and Mitsamiouli Center Hospital (☆) where P. falciparum isolates were collected
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directly sequenced in both directions, using an ABI
PRISM3730 DNA sequencer (Sangon Bio Inc., Shanghai,
China). The nucleotide and amino acid sequences of
K13-propeller were compared with wild-type amino acid
sequence (GenBank accession number, XM_001350122)
using Clustal W of the BioEdit 7.0 and MEGA 4.0
programs.
Statistical analysis
Statistical significance was determined with SPSS soft-
ware (version 13.0). Mann–Whitney U test was used to
compare in the prevalence of the mutations and alleles
of parasite samples between two collected periods.
Statistical significance was set at P < 0.05.
Results
All blood samples (n = 207) were collected from P.
falciparum mono-species infections identified after
microscopy examination of blood smears. Because of
low parasitemia and/or poor DNA quality, we were not
able to successfully amplify the P. falciparum K13-
propeller gene from all the samples; only 87.0 % of the P.
falciparum isolates from Grande Comore Island (n = 180)
could be amplified, including samples collected during
2006–2007 (n = 95) and 2013–2014 (n = 85). Sequencing
of the gene revealed only one synonymous mutation at co-
dons G538G (GGT→GGA) among the isolates from
2006 to 2007 group (1.1 % of the isolates examined, 1/95)
(Table 2). Three synonymous substitutions, R471R
(CGT→CGC), Y500Y (TAT→TAC), and G538G
(GGT→GGA) were found in isolates from 2013 to 2014
(5.9 % of the isolates examined, 5/85). Interestingly,
G538G substitution was detected in isolates from both
groups. Meanwhile, non-synonymous mutations at codons
S477Y and D584E, with the frequencies of 2.2 % (2/95),
were detected in isolates from 2006 to 2007. In contrast,
more than 20 % (18/85) of the isolates from 2013 to 2014
carried seven non-synonymous mutations (D464H,
D464Y, S477Y, L488S, A504T, I526M, A578S, and D584E)
in the K13-propeller domain, including two mutations
(S477Y and A578S) that have been reported previously in
Africa (Kenya and Uganda). Of these mutations, the most
prevalent change was D464H/Y (5.9 %, 5/85), followed by
A578S (4.7 %, 4/85) and D584E (3.5 %, 3/85). The number
of non-synonymous mutations increased significantly
from 2.2 % (in 2006–2007) to 21.2 % (in 2013–2014) (P <
0.05) in Grande Comore isolates. However, none of the
C580Y, R539T, or Y493H mutations previously associated
with delayed parasite clearance in Southeast Asia isolates,
or the M476I substitution selected in vitro in a Tanzanian
strain, was observed in these parasite populations (Table 2).
Haplotype analysis of P. falciparum K13-propeller
gene in isolates from 2006 to 2007 revealed only three
distinct allelic forms (Table 3), including the wild-type
allele, and two single-mutant alleles (477Y and 584E). Of
the three allelic variants, the most prevalent allelic vari-
ant was wild-type allele (97.9 %, 93/97). Ten allelic vari-
ants [wild-type allele, seven single-mutant alleles (464H,
464Y, 477Y, 488S, 526M, 578S, and 584E), and two
double-mutant alleles (477Y/504T and 526M/578S)]
were detected in 85 isolates from 2013 to 2014, with
wild-type allele being predominant (81.2 %, 69/85). The
remaining allelic variants were evenly distributed at low
frequency (1.2 to 3.5 %) among isolates from 2013 to
2014. It should be noted that all three haplotypes [(wild-
type allele, and two single-mutant alleles (477Y and
584E)] detected in 2006–2007 isolates were also found
in 2013–2014. Over the course of 8 years (2006–2014),
the wild-type allele prevalence significantly decreased
from 97.9 to 81.2 % (P < 0.05), and the mutant alleles
prevalence significantly increased from 2.1 to 18.8 %
(P < 0.05) in Grande Comore isolates. However, no
significant differences in each measured mutated allelic
forms were found between 2006–2007 and 2013–2014
groups (P > 0.05).
Discussions
In Comoros, ACT has been introduced as the first-line
treatment for uncomplicated P. falciparum malaria since
2004 [4, 5]. Although ACT remains highly efficacious for
the treatment of falciparum malaria, and delayed parasite
clearance of ACT has not been noted in Comoros [28], it
is important to monitor the potential presence of
artemisinin-resistant P. falciparum populations because
the emergence and spread of artemisinin-resistant strains
in Southeast Asia-an epicenter of resistance to several
other anti-malarial drugs (CQ and SP) [9–15, 29]. Clinical
artemisinin resistance is defined as a reduced parasite
clearance rate, expressed as an increased parasite clear-
ance half-life or a persistence of microscopically detectable
Table 1 Primer sequences and cycling conditions used to amplify K13-propeller gene of Plasmodium falciparum isolatesa
Genesb Primersc PCR cycling conditions Product size Reference
K13-propeller (P) F: 5′-cggagtgaccaaatctggga-3′
R: 5′-gggaatctggtggtaacagc-3′
95 °C 5 min/[95 °C 30 s, 60 °C 90 s, 72 °C
90 s] × 40 cycles, 72 °C 10 min
2096 [12]
K13-propeller (S) F: 5′-gccaagctgccattcatttg-3′
R: 5′-gccttgttgaaagaagcaga-3′
95 °C 5 min/[95 °C 30 s, 60 °C 90 s, 72 °C
90 s] × 40 cycles, 72 °C 10 min
848 [12]
aP. falciparum isolates from Grande Comore Island, Union of Comoros
bP Primary PCR reaction, S Secondary PCR reaction
cF Forward primer, R Reverse primer
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Table 2 Prevalence of K13-propeller mutations in Plasmodium falciparum isolatesa
Areas Mutations Amino acid and
genetic changesb
Number of isolates (%)c
2006–2007 (n = 95) 2013–2014 (n = 85)
Mitsoudje Center Hospital Synonymous R471R (CGT→ CGC) 0 (0) 1 (1.2)
G538G (GGT→ GGA) 1 (1.1) 2 (2.4)
Non-synonymous D464H (GAT→ CAT) 0 (0) 1 (1.2)
D464Y (GAT→ TAT) 0 (0) 1 (1.2)
L488S (TTG→ TCG) 0 (0) 1 (1.2)
I526M (ATA→ ATG) 0 (0) 1 (1.2)
A578S (GCT→ TCT) 0 (0) 2 (2.4)
D584E (GAT→ GAA) 1 (1.1) 1 (1.2)
National Malaria Center Synonymous Y500Y (TAT→ TAC) 0 (0) 1 (1.2)
Non-synonymous D464H (GAT→ CAT) 0 (0) 1 (1.2)
S477Y (TCT→ TAT) 0 (0) 1 (1.2)
I526M (ATA→ ATG) 0 (0) 1 (1.2)
A578S (GCT→ TCT) 0 (0) 2 (2.4)
Mitsamiouli Center Hospital Synonymous Y500Y (TAT→ TAC) 0 (0) 1 (1.2)
Non-synonymous D464Y (GAT→ TAT) 0 (0) 2 (2.4)
S477Y (TCT→ TAT) 1 (1.1) 1 (1.2)
A504T (GCT→ ACT) 0 (0) 1 (1.2)
D584E (GAT→ GAA) 0 (0) 2 (2.4)
aIsolates collected from 2006 to 2007 and 2013 to 2014 along Grande Comore Island of Comoros
bThe mutated amino acids and nucleotides are indicated in bold type
cStatistically significant differences for comparison with isolates circulating in 2006–2007 from Grande Comore Island (*P < 0.05) using Mann–Whitney U test
Table 3 Prevalence of single nucleotide polymorphisms and multi-mutated haplotypes in Plasmodium falciparum K13-propeller genea
Areas Genotypes Number of isolates (%)b
2006–2007 (n = 95) 2013–2014 (n = 85)
Mitsoudje Center Hospital Wild-type haplotype D464S477L488A504I526A578D584 30 (31.6) 20 (23.5)*
Single-mutant haplotype H464S477L488A504I526A578D584 0 (0) 1 (1.2)
Single-mutant haplotype Y464S477L488A504I526A578D584 0 (0) 1 (1.2)
Single-mutant haplotype D464S477S488A504I526A578D584 0 (0) 1 (1.2)
Single-mutant haplotype D464S477L488A504I526S578D584 0 (0) 1 (1.2)
Single-mutant haplotype D464S477L488A504I526A578E584 1 (1.1) 1 (1.2)
Double-mutant haplotype D464S477L488A504M526S578D584 0 (0) 1 (1.2)
National Malaria Center Wild-type haplotype D464S477L488A504I526A578D584 45 (47.4) 33 (38.9)*
Single-mutant haplotype H464S477L488A504I526A578D584 0 (0) 1 (1.2)
Single-mutant haplotype D464Y477L488A504I526A578D584 0 (0) 1 (1.2)
Single-mutant haplotype D464S477L488A504M526A578D584 0 (0) 1 (1.2)
Single-mutant haplotype D464S477L488A504I526S578D584 0 (0) 2 (2.4)
Mitsamiouli Center Hospital Wild-type haplotype D464S477L488A504I526A578D584 18 (18.9) 16 (18.8)
Single-mutant haplotype Y464S477L488A504I526A578D584 0 (0) 2 (2.4)
Single-mutant haplotype D464Y477L488A504I526A578D584 1 (1.1) 0 (0)
Single-mutant haplotype D464S477L488A504I526A578E584 0 (0) 2 (2.4)
Double-mutant haplotype D464Y477L488T504I526A578D584 0 (0) 1 (1.2)
Note: The double mutants were confirmed in repeated amplification and sequencing experiments
aIn isolates collected from 2006 to 2007 and 2013 to 2014 along Grande Comore Island, Union of Comoros. The mutated amino acids are indicated by bold type
bStatistically significant differences for comparison with isolates circulating in 2006–2007 from Grande Comore Island (*P < 0.05) using Mann–Whitney U test
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parasites on the third day of ACT. The half-life parameter
correlates strongly with results from the in vitro ring-stage
survival assay (RSA0–3 h) and results from the ex vivo
RSA. Unfortunately, due to poor field conditions (frequent
power outage and the lack of liquid N2 storage and in
vitro parasite culture), we were not able to culture P.
falciparum parasites collected from Grande Comore
Island for RSA0–3 assay. At present, we are not sure
whether the point mutations in K13-propeller gene can
serve as molecular markers for detecting potential artemi-
sinin resistance and for monitoring malaria-control mea-
sures in Comoros. This study investigated the prevalence
of mutant SNPs in K13-propeller gene of Grande Comore
P. falciparum isolates collected from two different periods
(2006–2007 and 2013–2014). Our data indicated that the
frequencies of non-synonymous mutations in K13-
propeller significantly increased in isolates from 2013 to
2014 when compared with those from 2006 to 2007. How-
ever, none of the mutations (C580Y, R539T, Y493H, and
M476I) previously associated with artemisinin resistance in
Southeast Asia parasites [12, 13, 25, 26] was observed in
the parasite populations collected from both examined pe-
riods, suggesting that P. falciparum populations in Grande
Comore are still effectively susceptible to artemisinin.
Our data were in line with other reports describing
K13-propeller polymorphisms in P. falciparum collected
from Africa, in which 24 non-synonymous mutations were
detected at low frequencies, and most of them were differ-
ent from the mutations observed in Southeast Asia when
more than 2600 samples were analyzed from 15 countries
[30–32]; Meanwhile, with the exception of 1 case in
Nigeria and 2 cases in Congo, there were no reported
cases of delayed parasite clearance or of prolonged
RSA0–3 hours in sub-Saharan Africa to date [13, 33].
These observations suggest that not all K13-propeller
mutations are associated with artemisinin resistance,
and that secondary loci are involved in resistance Asian
parasites, but not in African parasites. Additionally, high
levels of antimalarial immunity can mask a resistance
phenotype [34]. Unlike in Southeast Asia, individuals in
malaria-endemic regions of sub-Saharan Africa are less
likely to be infected with clonal parasites because of the
high transmission intensity and are thus likely to lose
potential resistance-conferring alleles to outcrossing. It is
known that the subpopulations of parasites can be catego-
rized as artemisinin-susceptible or -resistant, based on their
genetic profile [35]. Therefore, the different polymorphisms
in K13-propeller gene observed between Southeast Asia
and Africa may be due to different genetic backgrounds.
Whether the K13-propeller SNPs we observe here can be
used as molecular markers for artemisinin resistance glo-
bally requires further investigations considering various pa-
rameters such as malaria parasite ancestry, geographical,
clinical, epidemiological, and genetic diversities [31].
This study identified three synonymous mutations
(R471R, Y500Y, and G538G) in K13-propeller in 3.3 %
(6/180) of examined isolates. Of these mutations, muta-
tion at codon G538G was detected in both examined pe-
riods (2006–2007 and 2013–2014) with the similarly low
frequency (less than 3 %), indicating that the emergence
of parasites with synonymous mutation at codon G538G
should not attribute to artemisinin selective pressure on
Grande Comore Island. In the present study, two syn-
onymous mutations (Y500Y and G538G) were reported
from parasite population in Kenya [36]. Similarly, R471R
synonymous mutation found in this study was observed
in Congo [30], Gabon [31], and Angola [37]. Although
these synonymous mutations should not affect K13-
propeller protein structure and function and likely plays
no role in artemisinin resistance, the paucity of shared
synonymous mutation between Comoros’ and African
parasites suggesting that there exists a large reservoir of
K13-propeller polymorphisms globally.
It has been suggested that Y493H, I543T, R539T, and
C580Y mutations in K13-propeller gene are associated
with prolonged parasite survival ex vivo; Y493H, R539T,
and C580Y mutations are linked to in vivo delayed para-
site clearance; and M476I mutation is related to artemi-
sinin tolerance in vitro [12, 13, 25, 26]. In the present
study, only two mutations at codons S477Y (1.1 %) and
D584E (1.1 %) and two mutated-allelic types were de-
tected in isolates from 2006 to 2007, suggesting that P.
falciparum isolates collected in 2006–2007 showed very
limited variability within the K13-propeller gene. In con-
trast, mutations at positions 464 (5.9 %), 477 (2.4 %),
488 (1.2 %), 504 (1.2 %), 526 (2.4 %), 578 (4.7 %), and
584 (3.5 %) leading to nine mutated allelic types (18.8 %)
in K13-propeller gene were detected in isolates from
2013 to 2014. Our data was similar to those in other re-
ports, where three of the 18 imported malaria isolates
(16.7 %) from the Grande Comore showed polymorph-
ism (N490H, N554K and E596G), and double-mutant
haplotype occurred at very low frequencies [38]. The
data in the current study showed that a trend of increase
in the number of polymorphismic sites in P. falciparum
K13-propeller gene is presented in Grande Comore iso-
lates through the years of sample collection, may be due
to the selective artemisinin pressure continually from
the long history of ACT use since 2004. However, muta-
tions strongly associated with artemisinin resistance
(C580Y, R539T, Y493H, and M476I) in Southeast Asia
parasites were not observed in isolates from both
examined periods in the present study. Our observation
is consistent with those in previous reports from Kenya
[36], Angola [37], Mozambique [37], Senegal [39], Ugan-
dan [40] as well as other areas of Sub-Saharan Africa
[30], Caribbean’s Haiti [41], and South Asia’ Bangladesh
[42], where the K13-propeller gene mutations associated
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with artemisinin resistance were absent. Additionally,
trials of ACT for treating uncomplicated P. falciparum
malaria in Uganda [43], Kenya [44], and Mozambique
[45] have found 28-day PCR-corrected cure rates of
89 % or greater. Thus, our data is strongly suggesting
that many Grande Comore P. falciparum isolates col-
lected in 2013–2014 are likely still sensitive to artemisi-
nin even under the drug selective pressure from
introduction of ACT as the first-line treatment since
2004. Additionally, our results also suggest that selective
artemisinin drug pressure may exist in Grande Comore
Island that promotes these mutations, but not substan-
tially enough to lead clinical drug resistance. Whether or
not the non-synonymous substitutions in K13-propeller
gene observed in our study are associated with artemisi-
nin drug response, can not be inferred from our results.
However, these mutations in K13-propeller gene ob-
served in our study may provide some background
mutations setting the stage for emergence of artemisinin
resistance. Studies of careful comparison of parasites
with these allelic types and their response to artemisinin
are necessary to determine whether these mutations
contribute artemisinin resistance.
Recently, it was reported that highly artemisinin-
resistant parasites could have emerged independently in
Southeast Asia [26]. In the present study, seven non-
synonymous mutations were detected among the 180
Grande Comore isolates. Of these mutations, five
occurred at positions 464, 488, 504, 526, and 584. These
mutations present new mutations that have not been
previously reported in other endemic areas, suggesting
that independent emergence of the same mutations may
occur on Grande Comore Island. Notably, the S477Y
mutation detected in the present study was comparable
to those reported in other areas of the world, such as
Kenya [36]. Similarly, the A578S mutation detected in
Grande Comore Island isolates was concordance with
previous reports in Kenya [36], Uganda [30, 40], South
Asia’ Bangladesh [42] and Cambodia [12]. Therefore, our
data suggested that these mutations in K13-propeller
gene of P. falciparum populations have a global distribu-
tion. But it remains an open question as to whether the
presence of A578S mutation in these samples was due to
independent emergence or had spread from other areas.
Protein modeling data suggest that A578S can alter the
function of the K13 propeller protein because it lies
adjacent to the C580Y mutation that can cause delayed
parasite clearance in Cambodia [42]. Nevertheless, the
artemisinin collaboration group also found the A578S
mutation in one specimen within their study areas but this
mutation was not associated with increased parasite clear-
ance half-life [12]. In addition, other mutation (V566I) is
also located close to the C580Y mutation [12, 31]; how-
ever, whether V566I mutation has the same ability to alter
the function of K13 protein required further investigation.
Due to the presence of many different mutations among
parasites from various endemic regions, further studies
are required to validate the effect of the mutations.
Conclusion
Results from the current study showed that the number of
mutations in the P. falciparum K13-propeller gene has
significantly increased in Grande Comore isolates from
2006 to 2014. However, none of the mutations (C580Y,
R539T, Y493H, or M476I) previously associated to artemi-
sinin resistance in Southeast Asia parasites was observed
in parasite populations collected from the Grande Comore
Island (2006–2007 and 2013–2014). Although we were
not able to collect data related to the in vivo or in vitro ef-
ficacy of ACT on parasites in this study, the results sug-
gest that P. falciparum populations on Grande Comore
Island are still susceptible to artemisinin, even under
widespread drug selective pressure from the introduction
of ACT as the first-line treatment for over 10 years. Care-
ful monitoring of parasite populations on changes in the
K13-propeller gene and genes known to play a role in re-
sistant to other antimalarial drugs are necessary.
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